A case report of deferasirox-induced kidney injury and Fanconi syndrome

Wisconsin Medical Journal

Volumn 112, Issue 4, 2013, Pages 177-180

  Murphy, Noreen ^a   Elramah, Mohsen ^a   Vats, Hemender ^a   Zhong, Weixong ^a   Chan, Micah R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CREATININE; DEFERASIROX; FERRITIN; PHOSPHORUS; POTASSIUM;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANOREXIA; ARTICLE; CASE REPORT; CHELATION THERAPY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EWING SARCOMA; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; IRON OVERLOAD; KIDNEY BIOPSY; KIDNEY INJURY; MALE; METABOLIC ACIDOSIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHOSPHATE INTAKE; POTASSIUM EXCRETION; POTASSIUM INTAKE; POTASSIUM URINE LEVEL; PROTEINURIA; URINALYSIS;

BENZOATES; FANCONI SYNDROME; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; RENAL INSUFFICIENCY; TRIAZOLES; YOUNG ADULT;

EID: 84881643522     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Andreoli T, Carpenter C, Griggs R, Loscalzo J. Cecil Essentials of Medicine. 6th ed. Philadelphia, Pa: WB Saunders; 2004:256-257, 572-573.
2. Rafat C, Fakhouri, F, Ribeil JA, Delarue R, Le Quintec M. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54(5):931-934.
3. Olivieri NF, Brittenham GM. Iron chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761.
4. Hershko C. Treating iron overload: The state of the art. Semin Hematol. 2005;42(2 Suppl 1):S2-S4.
5. Piga A, Longo F, Consolati A. Mortality and morbidity in thalassemia with conventional treatment. Bone Marrow Transplant. 1977;19(Suppl 2):11-13.
6. Exjade (deferasirox) [prescribing information]. Stein, Switzerland: Novartis Pharmaceuticals Corp; 2011. http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf. Accessed July 16, 2013.
7. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant. 2008;23(10):3356-3358.
8. Yusuf B, McPhedran P, Brewster UC. Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Am J Kidney Dis. 2008;52(3):587-590.
9. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible Fanconi syndrome. Am J Hematol. 2010;85(2):132-134.
10. Grange S, Bertrand D, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25(7):2376-2378.
11. Yew CT, Talaulikar GS, Falk MC, Clayton P, D'Rozario J, Brown M. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology. 2010;15(3):377.
12. Wei HY, Yang CP, Cheng CH, Lo FS. Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion. 2011;51(5):949-954.
13. Rheault M, Bechtel H, Neglia J, Kashtan C. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56(4):674-676.
14. Hider RC. Charge states of deferasirox-ferric iron complexes. Am J Kidney Dis. 2010;55(3):614-615.
15. European Medicines Agency. Exjade: European Public Assessment Report (EPAR). Scientific Discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000670/WC500033929.pdf. Published April 17, 2007. Accessed July 15, 2013.